Literature DB >> 10799459

Susceptibility of Vibrio cholerae O139 to antibody-dependent, complement-mediated bacteriolysis.

S R Attridge1, F Qadri, M J Albert, P A Manning.   

Abstract

Volunteer studies with Vibrio cholerae O1 have shown that the best correlate of a vaccine's protective efficacy is its propensity to elicit serum bactericidal responses in its recipients. Attempts to detect such responses following infection with V. cholerae O139, however, have met with varying success. Using a tube-based assay which involves viable counting, we now report that strains of serogroup O139 can appear to be sensitive or resistant to a fixed concentration of complement in the presence of antibody, depending on assay conditions. Susceptibility to lysis is critically dependent on the availability of complement, but with O139 indicator strains this is not simply determined by the concentration of serum added to the reaction mix. The nature of the assay diluent and the concentration of indicator bacteria can also dramatically affect bactericidal end points, whereas such variables have minimal significance with O1 indicator bacteria. Although some laboratories use unencapsulated mutant strains to seek evidence of seroconversion following exposure to V. cholerae O139, this is not necessary, and our findings question the significance of capsule expression as a determinant of complement sensitivity when antibody is present. The medium used for growth of the indicator strain and the particular strain used appeared to be unimportant. Each of seven O139 isolates tested was found to be lysed by antibody and complement in our standard assay system, which allowed the detection of significant serum bactericidal responses in 9 of 11 cases of O139 disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10799459      PMCID: PMC95892          DOI: 10.1128/CDLI.7.3.444-450.2000

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  21 in total

1.  Vibrio cholerae O139 synonym bengal is closely related to Vibrio cholerae El Tor but has important differences.

Authors:  J A Johnson; C A Salles; P Panigrahi; M J Albert; A C Wright; R J Johnson; J G Morris
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

2.  The role of toxin-coregulated pili in the pathogenesis of Vibrio cholerae O1 El Tor.

Authors:  S R Attridge; E Voss; P A Manning
Journal:  Microb Pathog       Date:  1993-12       Impact factor: 3.738

3.  Large epidemic of cholera-like disease in Bangladesh caused by Vibrio cholerae O139 synonym Bengal. Cholera Working Group, International Centre for Diarrhoeal Diseases Research, Bangladesh.

Authors: 
Journal:  Lancet       Date:  1993-08-14       Impact factor: 79.321

4.  Surface co-expression of Vibrio cholerae and Salmonella typhi O-antigens on Ty21a clone EX210.

Authors:  S R Attridge; D Daniels; J K Morona; R Morona
Journal:  Microb Pathog       Date:  1990-03       Impact factor: 3.738

5.  Spread of Vibrio cholerae O139 Bengal in India.

Authors:  G B Nair; T Ramamurthy; S K Bhattacharya; A K Mukhopadhyay; S Garg; M K Bhattacharya; T Takeda; T Shimada; Y Takeda; B C Deb
Journal:  J Infect Dis       Date:  1994-05       Impact factor: 5.226

6.  The Vibrio cholerae O139 serogroup antigen includes an O-antigen capsule and lipopolysaccharide virulence determinants.

Authors:  M K Waldor; R Colwell; J J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

7.  Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1.

Authors:  F Qadri; G Mohi; J Hossain; T Azim; A M Khan; M A Salam; R B Sack; M J Albert; A M Svennerholm
Journal:  Clin Diagn Lab Immunol       Date:  1995-11

8.  In vitro production of toxin-coregulated pili by Vibrio cholerae El Tor.

Authors:  E Voss; S R Attridge
Journal:  Microb Pathog       Date:  1993-10       Impact factor: 3.738

9.  The capsule and O antigen in Vibrio cholerae O139 Bengal are associated with a genetic region not present in Vibrio cholerae O1.

Authors:  L E Comstock; D Maneval; P Panigrahi; A Joseph; M M Levine; J B Kaper; J G Morris; J A Johnson
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

10.  Genesis of the novel epidemic Vibrio cholerae O139 strain: evidence for horizontal transfer of genes involved in polysaccharide synthesis.

Authors:  E M Bik; A E Bunschoten; R D Gouw; F R Mooi
Journal:  EMBO J       Date:  1995-01-16       Impact factor: 11.598

View more
  9 in total

1.  Sensitive microplate assay for detection of bactericidal antibodies to Vibrio cholerae O139.

Authors:  Stephen R Attridge; Camilla Johansson; Dang D Trach; Firdausi Qadri; Ann-Mari Svennerholm
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

2.  Reduction in capsular content and enhanced bacterial susceptibility to serum killing of Vibrio cholerae O139 associated with the 2002 cholera epidemic in Bangladesh.

Authors:  Firdausi Qadri; Ann-Mari Svennerholm; Sohel Shamsuzzaman; Taufiqur Rahman Bhuiyan; Jason B Harris; A N Ghosh; G Balakrish Nair; Andrej Weintraub; Shah M Faruque; Edward T Ryan; David A Sack; Stephen B Calderwood
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

3.  Vibriocidal assays to determine the antibody titer of patient sera samples.

Authors:  Mike S Son; Ronald K Taylor
Journal:  Curr Protoc Microbiol       Date:  2011-11

4.  The utility of human challenge studies in vaccine development: lessons learned from cholera.

Authors:  Debbie-Ann T Shirley; Monica A McArthur
Journal:  Vaccine (Auckl)       Date:  2011-10

5.  Detection of antibodies to toxin-coregulated pili in sera from cholera patients.

Authors:  Stephen R Attridge; Gun Wallerström; Firdausi Qadri; Ann-Mari Svennerholm
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

6.  Construction and evaluation of V. cholerae O139 mutant, VCUSM21P, as a safe live attenuated cholera vaccine.

Authors:  Chandrika Murugaiah; Nik Zuraina Nik Mohd Noor; Shyamoli Mustafa; Ravichandran Manickam; Lalitha Pattabhiraman
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

7.  A Novel Luminescence-Based Serum Bactericidal Assay for Vibrio cholerae Reduces Assay Variation, Is Time- and Cost-Effective, and Directly Measures Continuous Titer Values.

Authors:  Taylor A Wahlig; Ben J Brintz; Melanie Prettyman; Andrew S Azman; Daniel T Leung
Journal:  Am J Trop Med Hyg       Date:  2021-07-08       Impact factor: 2.345

8.  Serogroup conversion of Vibrio cholerae in aquatic reservoirs.

Authors:  Melanie Blokesch; Gary K Schoolnik
Journal:  PLoS Pathog       Date:  2007-06       Impact factor: 6.823

9.  Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139.

Authors:  Mohammad Kamruzzaman; Meagan Kelly; Pavol Kováč; Peng Xu; Edward T Ryan; Richelle C Charles; Jason B Harris; Stephen B Calderwood; Aklima Akter; Rajib Biswas; M Hasanul Kaisar; Taufiqur R Bhuiyan; Louise C Ivers; Ralph Ternier; Jean-Gregory Jerome; Hélene B Pfister; Xiaowei Lu; Sameh E Soliman; Bart Ruttens; Rina Saksena; Jana Mečárová; Alžbeta Čížová; Firdausi Qadri; Slavomír Bystrický
Journal:  mSphere       Date:  2021-07-07       Impact factor: 4.389

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.